Tumor antigen-specific T cells recognizing Wilms tumor 1, BCR-ABL, and myeloma-associated antigens (TAA-specific T cells)

Tumor antigen-specific T cells recognizing WT1, BCR-ABL, and myeloma-associated antigens represent an adoptive cellular immunotherapy approach designed to treat hematologic malignancies. These T cells are typically generated by stimulating peripheral blood mononuclear cells with peptide libraries corresponding to specific oncogenic proteins such as Wilms Tumor 1 (WT1), the BCR-ABL fusion tyrosine kinase, and antigens prevalent in multiple myeloma like MAGE-A3 or PRAME (Source: PubMed, PMID: 26034293). The biological function of these cells is to provide a targeted immune response where the T-cell receptors (TCRs) recognize processed antigen fragments presented by Major Histocompatibility Complex (MHC) molecules on tumor cells (Source: StatPearls, NBK536932). This recognition triggers the release of cytotoxic granules, leading to the selective destruction of malignant cells while potentially establishing long-term immunological memory to prevent disease recurrence. This multi-antigen targeting strategy is specifically engineered to overcome tumor heterogeneity and the risk of antigen escape that often occurs with single-target therapies (Source: Marker Therapeutics). Clinical applications primarily focus on high-risk leukemia and myeloma patients, often in the context of post-allogeneic hematopoietic stem cell transplantation to enhance the graft-versus-tumor effect. This entry is classified as incorrect because it describes a therapeutic cell product and a list of multiple antigens rather than a single molecular target or receptor.

Other names

Multi-antigen-specific T cellsTAA-T cellsMulti-TAA-specific T cellsTumor-associated antigen-specific T cellsAdoptive T-cell therapy

Recognition of tumor-associated antigen (TAA) peptides presented by Major Histocompatibility Complex (MHC) molecules on the surface of malignant cells via endogenous or engineered T-cell receptors (TCRs), resulting in the release of perforins and granzymes to induce target cell apoptosis.